Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). (Q30275257)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 June 2017

Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). (English)

1 reference

Europe PubMed Central

14 June 2017

0 references

tropical medicine and hygiene

1 reference

based on heuristic

inferred from title

Selma M B Jeronimo

9

object named as

Selma Jeronimo

1 reference

Europe PubMed Central

14 June 2017

author name string

Naomi Aronson

1

1 reference

Europe PubMed Central

14 June 2017

Barbara L Herwaldt

2

1 reference

Europe PubMed Central

14 June 2017

Michael Libman

3

1 reference

Europe PubMed Central

14 June 2017

Richard Pearson

4

1 reference

Europe PubMed Central

14 June 2017

Rogelio Lopez-Velez

5

1 reference

Europe PubMed Central

14 June 2017

Peter Weina

6

1 reference

Europe PubMed Central

14 June 2017

Edgar M Carvalho

7

1 reference

Europe PubMed Central

14 June 2017

Moshe Ephros

8

1 reference

Europe PubMed Central

14 June 2017

Alan Magill

10

1 reference

Europe PubMed Central

14 June 2017

language of work or name

0 references

publication date

14 November 2016

1 reference

Europe PubMed Central

14 June 2017

Clinical Infectious Diseases

1 reference

Europe PubMed Central

14 June 2017

63

1 reference

Europe PubMed Central

14 June 2017

e202-e264

1 reference

Europe PubMed Central

14 June 2017

12

1 reference

Europe PubMed Central

14 June 2017

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Interventions for Old World cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmaniasis following local trauma: a clinical pearl

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania and HIV co-infection: dermatological manifestations

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania major Cutaneous Leishmaniasis in HIV-Positive Patients Does Not Spread to Extralesional Sites

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Comparative study of cutaneous leishmaniasis in human immunodeficiency virus (HIV)-infected patients and non-HIV-infected patients in French Guiana.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

American tegumentary leishmaniasis and HIV-AIDS association in a tertiary care center in the Brazilian Amazon

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The relationship between leishmaniasis and AIDS: the second 10 years

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Unusual manifestations of tegumentary leishmaniasis in AIDS patients from the New World.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Diffuse cutaneous leishmaniasis in an HIV-positive patient in western Africa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmania in HIV patient in Ouagadougou: clinical and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Caseating granulomas in cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucocutaneous leishmaniasis: an imported infection among travellers to central and South America

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal leishmaniasis and abnormalities on computed tomographic scans of paranasal sinuses

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal leishmaniasis ("espundia" Escomel, 1911).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Non-invasive cytology brush PCR diagnostic testing in mucosal leishmaniasis: superior performance to conventional biopsy with histopathology

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical aspects of visceral leishmaniasis in HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

HIV/AIDS-related visceral leishmaniasis: a clinical and epidemiological description of visceral leishmaniasis in northern Brazil.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical characteristics and treatment outcome of patients with visceral leishmaniasis and HIV co-infection in northwest Ethiopia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis as an opportunistic infection in HIV-infected patients: determinants of relapse and mortality in a collaborative study of 228 episodes in a Mediterreanean region

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Kaposi’s sarcoma-like lesions and other nodules as cutaneous involvement in AIDS-related visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Post-kala-azar dermal leishmaniasis in HIV-infected patients with AIDS: a report of two cases diagnosed in the USA.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Post-kala-azar dermal leishmaniasis due to Leishmania infantum in a human immunodeficiency virus type 1-infected patient

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Post-kala-azar dermal leishmaniasis associated with AIDS.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

[Leishmania infantum/HIV co-infection: cutaneous lesions following treatment of visceral leishmaniasis]

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Diagnostic performance of filter paper lesion impression PCR for secondarily infected ulcers and nonulcerative lesions caused by cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Molecular diagnosis of leishmaniasis: current status and future applications

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Real-time PCR assay for detection and quantification of Leishmania (Viannia) organisms in skin and mucosal lesions: exploratory study of parasite load and clinical parameters.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The immunological, environmental, and phylogenetic perpetrators of metastatic leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Disseminated Leishmaniasis: A New and Emerging Form of Leishmaniasis Observed in Northeastern Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A proposed new clinical staging system for patients with mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Laboratory diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A comparison of intercostal and abdominal routes of splenic aspiration and bone marrow aspiration in the diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Peripheral blood buffy coat smear: a promising tool for diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Noninvasive molecular diagnosis of human visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Old world leishmaniasis: an emerging infection among deployed US military and civilian workers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Identification of Leishmania at the species level with matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Easy identification of leishmania species by mass spectrometry

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Species typing in dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Species-directed therapy for leishmaniasis in returning travellers: a comprehensive guide

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis among organ transplant recipients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Predictors of visceral leishmaniasis relapse in HIV-infected patients: a systematic review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Molecular diagnosis of leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Molecular tools for diagnosis of visceral leishmaniasis: systematic review and meta-analysis of diagnostic test accuracy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Quantification of Leishmania infantum DNA by a real-time PCR assay with high sensitivity

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Universal PCR assays for the differential detection of all Old World Leishmania species.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Is it time to revise the nomenclature of Leishmania?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Rapid immunochromatographic strip test for detection of anti-K39 immunoglobulin G antibodies for diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Accurate Serodetection of Asymptomatic Leishmania donovani Infection by Use of Defined Antigens

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Comparison of point-of-care tests for the rapid diagnosis of visceral leishmaniasis in East African patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Design, development and evaluation of rK28-based point-of-care tests for improving rapid diagnosis of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Serodiagnosis of leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The diagnostic accuracy of serologic and molecular methods for detecting visceral leishmaniasis in HIV infected patients: meta-analysis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The emergence of concurrent HIV-1/AIDS and visceral leishmaniasis in Northeast Brazil.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Specificity of the rapid rK39 antigen-based immunochromatographic test Kalazar Detect(r) in patients with cutaneous leishmaniasis in Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Advances in leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Imported mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Successful treatment of imported mucosal Leishmania infantum leishmaniasis with miltefosine after severe hypokalemia under meglumine antimoniate treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

New World cutaneous leishmaniasis in returned travellers: treatment failures using intravenous sodium stibogluconate

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

New world cutaneous leishmaniasis in travellers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal Leishmania infantum infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Therapeutic vaccines for leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Persistence of leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Morbidity and patient perception of flexible laryngoscopy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The epidemiology and control of leishmaniasis in Andean countries

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Presence of Leishmania RNA Virus 1 in Leishmania guyanensis Increases the Risk of First-Line Treatment Failure and Symptomatic Relapse

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Association of the Endobiont Double-Stranded RNA Virus LRV1 With Treatment Failure for Human Leishmaniasis Caused by Leishmania braziliensis in Peru and Bolivia.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B in comparison to sodium stibogluconate for Leishmania braziliensis cutaneous leishmaniasis in travelers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine for new world cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B treatment of cutaneous leishmaniasis due to Leishmania tropica

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Evaluation of treatment with pentamidine for cutaneous leishmaniasis in Suriname

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Evaluation of thermotherapy for the treatment of cutaneous leishmaniasis in Kabul, Afghanistan: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A randomized controlled trial of local heat therapy versus intravenous sodium stibogluconate for the treatment of cutaneous Leishmania major infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of local heat therapy by radiofrequency in the treatment of cutaneous leishmaniasis, compared with intralesional injection of meglumine antimoniate.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmaniasis: evaluation of 3,074 cases in the Cukurova region of Turkey

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Lymphatic Dissemination in Cutaneous Leishmaniasis Following Local Treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmaniasis responds to daylight-activated photodynamic therapy: proof of concept for a novel self-administered therapeutic modality.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of CO(2) laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

LeishMan recommendations for treatment of cutaneous and mucosal leishmaniasis in travelers, 2014.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Social impact of leishmaniasis, Afghanistan

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Randomized, double-blind, comparative clinical trial on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7% hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of cutaneous leishmaniasis with antimony: intramuscular versus intralesional administration

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Intralesional antimony for single lesions of bolivian cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Topical treatment of cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania tropica in northern Israel: a clinical overview of an emerging focus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Topical paromomycin with or without gentamicin for cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical manifestations and classification of Old World cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Methodology of clinical trials aimed at assessing interventions for cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Designing and reporting clinical trials on treatments for cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Decreased effect of glucantime in cutaneous leishmaniasis complicated with secondary bacterial infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis in immunosuppressed individuals

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmaniasis reactivation 2 years after treatment caused by systemic corticosteroids - first report

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Recurrent American cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Prediction score for antimony treatment failure in patients with ulcerative leishmaniasis lesions

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania antimony resistance: what we know what we can learn from the field.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Up-regulation of silent information regulator 2 (Sir2) is associated with amphotericin B resistance in clinical isolates of Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Susceptibility of clinical isolates of Leishmania aethiopica to miltefosine, paromomycin, amphotericin B and sodium stibogluconate using amastigote-macrophage in vitro model

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

American cutaneous leishmaniasis unresponsive to antimonial drugs: successful treatment using combination of N-methilglucamine antimoniate plus pentoxifylline

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Interventions for American cutaneous and mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal leishmaniasis . Current scenario and prospects for treatment.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Acute airway obstruction due to oedema of the larynx following antimony therapy in mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Evidence-based guidelines for laboratory screening for infectious diseases before initiation of systemic immunosuppressive agents in patients with autoimmune bullous dermatoses

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Reducing the risk of infection in a 74-year-old man who is to receive prednisone

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Screening, prevention, and treatment for hyperinfection syndrome and disseminated infections caused by Strongyloides stercoralis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical and immunological outcome in cutaneous leishmaniasis patients treated with pentoxifylline

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucocutaneous leishmaniasis treated with liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Strong association between serological status and probability of progression to clinical visceral leishmaniasis in prospective cohort studies in India and Nepal

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Therapeutic options for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B formulations and other drugs for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal and lipid formulations of amphotericin B. Clinical pharmacokinetics

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Two doses of a lipid formulation of amphotericin B for the treatment of Mediterranean visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Safety and efficacy of single dose versus multiple doses of AmBisome for treatment of visceral leishmaniasis in eastern Africa: a randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical epidemiology, diagnosis and treatment of visceral leishmaniasis in the Pokot endemic area of Uganda and Kenya

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of Brazilian kala-azar with a short course of amphocil (amphotericin B cholesterol dispersion).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of kala-azar in Brazil with Amphocil (amphotericin B cholesterol dispersion) for 5 days

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin-B-lipid complex.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A comparative evaluation of amphotericin B and sodium antimony gluconate, as first-line drugs in the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Injectable paromomycin for Visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Triad of Acute Infusion‐Related Reactions Associated with Liposomal Amphotericin B: Analysis of Clinical and Epidemiological Characteristics

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The safety of amphotericin B lipid complex in patients with prior severe intolerance to liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine for visceral and cutaneous leishmaniasis: drug characteristics and evidence-based treatment recommendations

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Oral miltefosine for Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Trial of oral miltefosine for visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Proteomic analysis of the soluble proteomes of miltefosine-sensitive and -resistant Leishmania infantum chagasi isolates obtained from Brazilian patients with different treatment outcomes

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

In vitro antileishmanial drug susceptibility of clinical isolates from patients with Indian visceral leishmaniasis--status of newly introduced drugs

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of visceral leishmaniasis in children in the Central-West Region of Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Challenges in the therapy of visceral leishmaniasis in Brazil: a public health perspective.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin versus pentamidine in antimony-unresponsive kala-azar

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Are there differences in clinical and laboratory parameters between children and adults with American visceral leishmaniasis?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Single-dose liposomal amphotericin B for visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Epidemic visceral leishmaniasis in southern Sudan: treatment of severely debilitated patients under wartime conditions and with limited resources

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Risk factors for in-hospital mortality of visceral leishmaniasis patients in eastern Uganda

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Risk factors for death in children with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Evaluation of PCR for diagnosis of Indian kala-azar and assessment of cure

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Polymerase chain reaction in the diagnosis and prognosis of Mediterranean visceral leishmaniasis in immunocompetent children

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A nested polymerase chain reaction for diagnosis and follow-up of human visceral leishmaniasis patients using blood samples.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Rapid clearance of circulating Leishmania kinetoplast DNA after treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A cloned antigen (recombinant K39) of Leishmania chagasi diagnostic for visceral leishmaniasis in human immunodeficiency virus type 1 patients and a prognostic indicator for monitoring patients undergoing drug therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Post-kala-azar dermal leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Burden of visceral leishmaniasis in villages of eastern Gedaref State, Sudan: an exhaustive cross-sectional survey

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis in the United States: treatment in 2012

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Parasite susceptibility to amphotericin B in failures of treatment for visceral leishmaniasis in patients coinfected with HIV type 1 and Leishmania infantum.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome)

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of leishmaniasis in HIV-positive patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B for the treatment of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparison

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

High parasitological failure rate of visceral leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Oral miltefosine for leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine for visceral leishmaniasis relapse treatment and secondary prophylaxis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral Leishmaniasis and HIV coinfection in East Africa

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Combination Treatment for Visceral Leishmaniasis Patients Coinfected with Human Immunodeficiency Virus in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Impact of highly active antiretroviral therapy on the incidence of visceral leishmaniasis in a French cohort of patients infected with human immunodeficiency virus

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

HIV-1 protease inhibitors for treatment of visceral leishmaniasis in HIV-co-infected individuals

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis as a Manifestation of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV-Infected Patients: A Literature Review

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

'Active chronic visceral leishmaniasis' in HIV-1-infected patients demonstrated by biological and clinical long-term follow-up of 10 patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B lipid complex versus no treatment in the secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Pentamidine as secondary prophylaxis for visceral leishmaniasis in the immunocompromised host: report of four cases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Use of Pentamidine As Secondary Prophylaxis to Prevent Visceral Leishmaniasis Relapse in HIV Infected Patients, the First Twelve Months of a Prospective Cohort Study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Prophylaxis of visceral leishmaniasis in human immunodeficiency virus-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania resistance to miltefosine associated with genetic marker

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Localized mucosal leishmaniasis due to Leishmania (Leishmania) infantum: clinical and microbiologic findings in 31 patients.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Oral leishmaniasis in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mucocutaneous leishmaniasis as presentation of HIV infection in Sardinia, insular Italy.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Tegumentary leishmaniasis as the cause of immune reconstitution inflammatory syndrome in a patient co-infected with human immunodeficiency virus and Leishmania guyanensis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Diffuse cutaneous leishmaniasis associated with the immune reconstitution inflammatory syndrome

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Uveitis due to Leishmania major as part of HAART-induced immune restitution syndrome in a patient with AIDS.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Immune response to Leishmania antigens in an AIDS patient with mucocutaneous leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome (IRIS): a case report

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmaniasis, an emerging infection in travelers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Patterns of illness in travelers visiting Mexico and Central America: the GeoSentinel experience

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Imported leishmaniasis: a heterogeneous group of diseases

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Holiday souvenirs from the Mediterranean: three instructive cases of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Transmission of Tropical and Geographically Restricted Infections during Solid-Organ Transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Parasitic infections in solid organ transplant recipients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in lung transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Risk factors, clinical features and outcomes of visceral leishmaniasis in solid-organ transplant recipients: a retrospective multicenter case-control study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania infantum leishmaniasis in corticosteroid--treated patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis and immunocompromise as a risk factor for the development of visceral leishmaniasis: a changing pattern at the hospital for tropical diseases, london

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in immunocompromised hosts

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Epidemiological changes in leishmaniasis in Spain according to hospitalization-based records, 1997-2011: raising awareness towards leishmaniasis in non-HIV patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Aspects of the association between leishmaniasis and malignant disorders

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in immunocompromised patients with and without AIDS: a comparison of clinical features and prognosis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Parasitic infections in solid organ transplantation

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Antimony to Cure Visceral Leishmaniasis Unresponsive to Liposomal Amphotericin B

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Clinical aspects and management of cutaneous leishmaniasis in rheumatoid patients treated with TNF-α antagonists

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in the early post-transplant period after kidney transplantation: clinical features and therapeutic management

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Recurrent leishmaniasis in kidney transplant recipients: report of 2 cases and systematic review of the literature.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

High prevalence of asymptomatic Leishmania spp. infection among liver transplant recipients and donors from an endemic area of Brazil.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment of American tegumentary leishmaniasis in special populations: a summary of evidence

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis (kala-azar) and pregnancy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis and pregnancy: analysis of cases reported in a central-western region of Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

A comparison of liposomal amphotericin B with sodium stibogluconate for the treatment of visceral leishmaniasis in pregnancy in Sudan

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Maternal and perinatal outcomes of visceral leishmaniasis (kala-azar) treated with sodium stibogluconate in eastern Sudan

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in pregnancy: a case series and a systematic review of the literature

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Mediterranean visceral leishmaniasis in pregnancy

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in pregnancy: a case report.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Visceral leishmaniasis in pregnancy - the role of amphotericin B.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Embryotoxicity of meglumine antimoniate in the rat.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Genotoxic effects of the antileishmanial drug Glucantime.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Development of miltefosine as an oral treatment for leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Atypical manifestations of tegumentary leishmaniasis in a transmission area of Leishmania braziliensis in the state of Bahia, Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Two women presenting worsening cutaneous ulcers during pregnancy: diagnosis, immune response, and follow-up.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Drug use and breastfeeding

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Leishmania tropica in children: a retrospective study

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Can a simple outpatient-based treatment be used to treat cutaneous leishmaniasis in young children? A Critically Appraised Topic.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Amphotericin B therapy in children with visceral leishmaniasis: daily vs. alternate day, a randomized trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

First-line liposomal amphotericin B for pediatric visceral leishmaniasis in southern France

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Systemic meglumine antimoniate in acute cutaneous leishmaniasis: children versus adults

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Phase IV trial of miltefosine in adults and children for treatment of visceral leishmaniasis (kala-azar) in Bangladesh

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Failure of miltefosine treatment for visceral leishmaniasis in children and men in South-East Asia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Optimal dosing of miltefosine in children and adults with visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Failure of miltefosine in visceral leishmaniasis is associated with low drug exposure

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Intralesional meglumine antimoniate for treatment of cutaneous leishmaniasis patients with contraindication to systemic therapy from Rio de Janeiro (2000 to 2006).

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

High mortality among older patients treated with pentavalent antimonials for visceral leishmaniasis in East Africa and rationale for switch to liposomal amphotericin B.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

The effect of age on the frequency of adverse reactions caused by antimony in the treatment of American tegumentary leishmaniasis in Governador Valadares, State of Minas Gerais, Brazil.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Monitoring toxicity associated with parenteral sodium stibogluconate in the day-case management of returned travellers with New World cutaneous leishmaniasis [corrected]

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Diffuse cutaneous leishmaniasis with mucosal involvement in Colombia, caused by an enzymatic variant of Leishmania panamensis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Treatment response of cutaneous leishmaniasis due to Leishmania aethiopica to cryotherapy and generic sodium stibogluconate from patients in Silti, Ethiopia

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

First Case of Cutaneous Reconstitution Inflammatory Syndrome Associated with HIV Infection and Leishmaniasis

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Liposomal amphotericin B for complicated visceral leishmaniasis (kala-azar) in eastern Sudan: how effective is treatment for this neglected disease?

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Highly Active Antiretroviral Therapy (HAART) Modifies the Incidence and Outcome of Visceral Leishmaniasis in HIV-Infected Patients

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIW670

21 January 2018

Identifiers

10.1093/CID/CIW670

1 reference

Europe PubMed Central

14 June 2017

1 reference

Europe PubMed Central

14 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30275257&oldid=1550670710"